WallStreetZenWallStreetZen

NYSE: PEN
Penumbra Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PEN past earnings growth

How has PEN's earnings growth performed historically?
Company
N/A
Industry
91.11%
Market
71.87%
PEN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PEN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PEN past revenue growth

How has PEN's revenue growth performed historically?
Company
24.95%
Industry
9.47%
Market
17.2%
PEN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PEN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PEN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PEN earnings and revenue history

Current Revenue
$1.1B
Current Earnings
$91.0M
Current Profit Margin
8.6%
PEN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

PEN Return on Equity

Current Company
8.3%
Current Industry
10.5%
Current Market
188%
PEN's Return on Equity (8.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PEN announces earnings.

PEN Return on Assets

Current Company
6.2%
Current Industry
5.3%
PEN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PEN Return on Capital Employed

Current Company
5.67%
Current Industry
8.3%
PEN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PEN vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PEN$1.06B$106.91M$90.95M+18.93%+65.65%
BIO$2.67B-$800.67M-$637.32M+3.13%N/A
MASI$2.05B$186.40M$81.50M+16.91%-15.94%
INSP$624.80M-$15.66M-$21.15M+65.32%N/A
GMED$1.57B$290.00M$122.87M+17.08%-7.39%
View Top Medical Device Stocks

PEN earnings dates

Next earnings date
Jun 5, 2024

Penumbra Earnings & Revenue FAQ

What were PEN's earnings last quarter?

On Invalid Date, Penumbra (NYSE: PEN) reported Q4 2023 earnings per share (EPS) of $1.41, up 1,181.82% year over year. Total Penumbra earnings for the quarter were $54.22 million. In the same quarter last year, Penumbra's earnings per share (EPS) was $0.11.

If you're new to stock investing, here's how to buy Penumbra stock.

What was PEN's earnings growth in the past year?

As of Q2 2024, Penumbra's earnings has grown year over year. Penumbra's earnings in the past year totalled $90.95 million.

What is PEN's earnings date?

Penumbra's earnings date is Invalid Date. Add PEN to your watchlist to be reminded of PEN's next earnings announcement.

What was PEN's revenue last quarter?

On Invalid Date, Penumbra (NYSE: PEN) reported Q4 2023 revenue of $284.68 million up 28.69% year over year. In the same quarter last year, Penumbra's revenue was $221.22 million.

What was PEN's revenue growth in the past year?

As of Q2 2024, Penumbra's revenue has grown 24.95% year over year. This is 15.49 percentage points higher than the US Medical Devices industry revenue growth rate of 9.47%. Penumbra's revenue in the past year totalled $1.06 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.